The relative risk for a second @entity5 after the diagnosis of @entity263 and the prognostic impact of the association of multiple primary @entity5 (MPMNs) in @entity1 with @entity263 were analyzed in a retrospective study. The development of MPMNs was examined in 312 consecutive @entity1 who had been diagnosed with @entity263 between 1966 and 1992. The population-based @entity5 incidence rates in Japan were utilized to calculate the expected number of MPMNs. Of the 312 @entity1 , 60 fulfilled the diagnosis of MPMNs. In 13 @entity1 , @entity263 and other @entity5 were diagnosed simultaneously. In 35 of the 312 @entity1 , @entity263 was the second or third @entity5 diagnosis. In the remaining 287 @entity1 , @entity263 developed initially. Of the 287 @entity1 , 12 developed a second @entity5 compared with 17 expected (relative risk 0.71, 95% confidence interval 0.45-1.4). No single anatomic site showed a significantly increased risk above that expected either. The overall survival of @entity1 with @entity263 was not reduced by the association with MPMNs. This may be explained by the fact that the stage of the @entity263 was lower in @entity1 with MPMNs than in @entity1 without MPMNs.

Multiple primary XXXX associated with @entity263 in 312 consecutive cases.

@entity5 :: ('MESH:D009369', 'Disease') :: ['primary malignancy', 'cancer', 'primary cancer', 'malignant neoplasms', 'malignancies'] @entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']
@entity5 :: (MESH:D009369,Disease) :: ['malignant neoplasms']
